



August 02, 2019

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Sub : Consolidated Financial Results for the Quarter and year ended 31 March 2019 – Correction in the figures

Ref : Disclosure of the Outcome of the Meeting of the Board of Directors of the Company made on May 23, 2019 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Stock Code : BSE – 539787, NSE – HCG

Dear Sir/Madam

We refer to the above disclosure made on May 23, 2019, along with the audited financial results of the company for the quarter and year ended 31 March 2019.

We wish to bring to your kind attention that, we have noticed in the Statement of Audited Consolidated Financial Results for the quarter and year ended 31 March 2019 (“**Consolidated Financial Results**”), the following figures were erroneously disclosed in the columns, “Year ended 31 March 2019” and “As at 31 March 2019” respectively:

(Rs in Lakhs)

Particulars	Amount as disclosed	Correct Amount
Reserves, i.e., ‘Other equity’ (Sl no. 13)	45,817	38,873
Other Financial Assets (Sl no. f (iii) under Non-Current Assets)	9,119	2,175
Other equity (Sl no. c under Equity)	45,817	38,873

These figures do not form part of any key performance indicators of the Company. The corrected Consolidated Financial Results are enclosed.

The other figures disclosed in the Consolidated Financial Results filed with the Stock Exchanges on May 23, 2019, remain unchanged.

Kindly take the above correction on record and acknowledge receipt of the same.

We are simultaneously uploading this intimation along with the corrected Consolidated Financial Results on the website of the Company: [www.hcgel.com](http://www.hcgel.com).

Thanking you,  
For **HealthCare Global Enterprises Limited**

**Sunu Manuel**  
**Company Secretary & Compliance Officer**  
Encl: a/a.

**HealthCare Global Enterprises Limited**

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | [info@hcgoncology.com](mailto:info@hcgoncology.com) | [www.hcgoncology.com](http://www.hcgoncology.com) | CIN : L15200KA1998PLC023489

Maruthi Info-Tech Centre  
11-12/1, B Block, 2nd Floor  
Inner Ring Road, Koramangala  
Bangalore 560 071 India

Telephone +91 80 7134 7000  
Fax +91 80 7134 7999

**Independent Auditors' Report on Annual Consolidated Financial Results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
Board of Directors of HealthCare Global Enterprises Limited

We have audited the annual consolidated financial results ("Statement") of HealthCare Global Enterprises Limited (hereinafter referred to as "the Holding Company"), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture as listed in Annexure I for the year ended 31 March 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the last quarter ended 31 March 2019 and the corresponding quarter ended in the previous year as reported in the Statement are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date consolidated figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter of the respective financial year have only been reviewed and not subjected to audit.

The Statement has been prepared from annual consolidated financial statements and reviewed quarterly consolidated financial results up to the end of the third quarter which are the responsibility of the Company's management. Our responsibility is to express an opinion on the Statement based on our audit of the annual consolidated financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit the financial statements of four subsidiaries and one step down subsidiary included in the Statement, whose annual financial statements reflect total assets of Rs. 17,393 lakhs as at 31 March 2019 as well as total revenue (including other income) of Rs. 2,638 lakhs for the year ended as on that date. The Statement also include the Group's share of net loss (and other comprehensive income) of Rs. 1,098 lakhs for the year ended 31 March 2019 in respect of an associate and a joint venture whose financial statement has not been audited by us. These annual financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the annual consolidated financial results, to the extent they have been derived from such annual financial statements is based solely on the report of such other auditors.

Our opinion on the annual consolidated financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

13

B S R & Co. LLP

**Independent Auditors' Report on Annual Consolidated Financial Results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)**

In our opinion and to the best of our information and according to the explanations given to us and based on consideration of reports of other auditors on separate financial statements of the subsidiaries, an associate and a joint venture as aforesaid, the Statement:

- (i) include the annual financial results of the entities as listed in Annexure 1;
- (ii) have been presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (iii) gives a true and fair view of the net consolidated loss and other comprehensive income and other financial information for the year ended 31 March 2019.

For B S R & Co. LLP  
*Chartered Accountants*  
Firm's Registration No: 101248W/W-100022

*Amit Somani*

Amit Somani  
*Partner*  
Membership No. 060154

Place: Bengaluru  
Date: 23 May 2019

## HealthCare Global Enterprises Limited

## Annexure 1: List of entities consolidated

Sl. No.	Name of the Entity	Subsidiary/ Associate/ Joint Venture	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
5	HCG NCHRI Oncology LLP	Subsidiary	India
6	HCG EKO Oncology LLP	Subsidiary	India
7	APEX HCG Oncology Hospitals LLP	Subsidiary	India
8	HCG Manavata Oncology LLP	Subsidiary	India
9	Niruja Product Development & Healthcare Research Private Limited (formerly known as MIMS HCG Oncology Private Limited)	Subsidiary	India
10	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
11	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
12	HCG Sun Hospitals LLP	Subsidiary	India
13	HCG (Mauritius) Private Limited	Step-down subsidiary	Mauritius
14	HealthCare Global (Africa) Private Limited Group (subsidiary till 30 June 2017)	Associate	Mauritius
15	Strand Life Sciences Private Limited (from 7 February 2018)	Joint Venture	India

h

## HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

## STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

(Rs. in Lakhs except share data)

Sl. No.	Particulars	3 months ended	Preceding 3	Corresponding 3	Year ended	Previous year
		31 March 2019	months ended 31 December 2018	months ended in the previous year 31 March 2018	31 March 2019	ended 31 March 2018
		(Refer note 1)	Unaudited	(Refer note 1)	Audited	Audited
1	<b>Income</b>					
	(a) Revenue from operations	25,710	24,820	22,037	97,602	82,879
	(b) Income from government grant	82	67	190	265	190
	(c) Other income	323	98	261	741	1,280
	<b>Total income</b>	<b>26,115</b>	<b>24,985</b>	<b>22,488</b>	<b>98,608</b>	<b>84,349</b>
2	<b>Expenses</b>					
	(a) Purchases of medical and non-medical items	5,683	5,558	4,584	22,149	19,664
	(b) Changes in inventories	27	101	245	(285)	(693)
	(c) Employee benefits expense	4,877	4,857	4,014	18,452	15,771
	(d) Finance costs	1,556	1,294	1,455	6,991	4,235
	(e) Depreciation and amortisation expense	2,280	2,193	2,128	8,509	7,146
	(f) Medical consultancy charges	5,560	5,676	4,116	21,138	17,422
	(g) Other expenses	6,425	5,801	6,049	23,894	19,023
	<b>Total expenses</b>	<b>26,408</b>	<b>25,480</b>	<b>22,591</b>	<b>100,848</b>	<b>82,568</b>
3	<b>Profit/ (loss) before share of loss of an associate / joint venture, exceptional items and tax (1-2)</b>	<b>(293)</b>	<b>(495)</b>	<b>(103)</b>	<b>(2,240)</b>	<b>1,781</b>
4	Share of profit/(loss) of an associate / joint venture, net of taxes	(525)	(228)	(121)	(1,098)	(140)
5	<b>Profit/ (loss) before exceptional items and tax (3+4)</b>	<b>(818)</b>	<b>(723)</b>	<b>(224)</b>	<b>(3,338)</b>	<b>1,641</b>
6	Exceptional items [refer note 4]	-	-	437	-	1,077
7	<b>Profit / (loss) before tax (5+6)</b>	<b>(818)</b>	<b>(723)</b>	<b>213</b>	<b>(3,338)</b>	<b>2,718</b>
8	<b>Tax expense</b>					
	- Current tax	(326)	8	500	(110)	1,355
	- Deferred tax	596	(128)	(271)	(140)	(331)
	<b>Total tax expense</b>	<b>270</b>	<b>(120)</b>	<b>229</b>	<b>(250)</b>	<b>1,024</b>
9	<b>Profit / (loss) for the period / year (7-8)</b>	<b>(1,088)</b>	<b>(603)</b>	<b>(16)</b>	<b>(3,088)</b>	<b>1,694</b>
10	<b>Other comprehensive income / expense</b>					
	(i) Items that will not be reclassified subsequently to profit or loss					
	- Remeasurements of the defined benefit plans	30	-	(25)	30	(25)
	- Exchange differences on translation of financial statements of foreign operations	12	(107)	-	114	-
	- Income tax effect on above	(9)	-	10	(9)	10
	(ii) Items that will be reclassified to profit or loss					
	- Effective portion of loss on hedging instruments in a cash flow hedge	(20)	(223)	-	(643)	-
	- Income tax on (ii) above	9	76	-	225	-
	<b>Other comprehensive income /expense for the period / year, net of taxes</b>	<b>22</b>	<b>(254)</b>	<b>(15)</b>	<b>(283)</b>	<b>(15)</b>
11	<b>Total comprehensive income/ (loss) for the period / year (9+10)</b>	<b>(1,066)</b>	<b>(857)</b>	<b>(31)</b>	<b>(3,371)</b>	<b>1,679</b>
	<b>Profit / (loss) for the period /year attributable to:</b>					
	Equity holders of the Company	(872)	(620)	259	(2,480)	2,052
	Non-controlling interests	(216)	17	(275)	(608)	(358)
	<b>Other comprehensive income / (loss) for the period / year attributable to</b>					
	Equity holders of the Company	18	(254)	(18)	(287)	(18)
	Non-controlling interests	4	-	3	4	3
	<b>Total comprehensive income / (loss) for the period / year attributable to</b>					
	Equity holders of the Company	(854)	(874)	241	(2,767)	2,034
	Non-controlling interests	(212)	17	(272)	(604)	(355)
12	Paid-up equity share capital (Face value of Rs. 10 each)	8,792	8,789	8,690	8,792	8,690
13	Reserves, i.e., 'Other equity'				38,873	39,822
14	<b>Earnings/(loss) per share (face value of Rs. 10 each)</b>	Not annualised	Not annualised	Not annualised	Annualised	Annualised
	(a) Basic	(0.99)	(0.71)	0.30	(2.82)	2.38
	(b) Diluted	(0.99)	(0.71)	0.30	(2.82)	2.38
	See accompanying notes to the Consolidated Financial Results					



STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

CONSOLIDATED BALANCE SHEET

(Rs in Lakhs)

Particulars	As at	As at
	31 March 2019	31 March 2018
	Audited	Audited
<b>A ASSETS</b>		
<b>I Non-current assets</b>		
(a) Property, plant and equipment	85,154	71,257
(b) Capital work in progress	15,263	17,397
(c) Goodwill	10,934	10,934
(d) Other intangible assets	933	581
(e) Investment in equity accounted investee	3,844	4,804
(f) Financial assets		
(i) Investments	1,061	513
(ii) Loans	3,673	986
(iii) Other financial assets	2,175	4,960
(g) Deferred tax assets (net)	2,686	2,310
(h) Income tax assets (net)	5,539	2,111
(i) Other non-current assets	6,797	6,504
<b>Total non current assets</b>	<b>138,059</b>	<b>122,357</b>
<b>II Current assets</b>		
(a) Inventories	2,677	2,403
(b) Financial assets		
(i) Trade receivables	15,689	12,844
(ii) Cash and cash equivalents	2,052	2,880
(iii) Bank balance other than cash and cash equivalents above	35	-
(iv) Loans	1,421	312
(v) Other financial assets	2,425	1,406
(c) Other current assets	2,997	2,165
<b>Total current assets</b>	<b>27,296</b>	<b>22,010</b>
<b>Total assets</b>	<b>165,355</b>	<b>144,367</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>I Equity</b>		
(a) Equity share capital	8,792	8,690
(b) Shares pending issuance ( refer note 5 )	-	2,998
(c) Other equity	38,873	39,822
<b>Equity attributable to equity holders of the Company</b>	<b>47,665</b>	<b>51,510</b>
Non- controlling interests	4,555	6,392
<b>Total equity</b>	<b>52,220</b>	<b>57,902</b>
<b>II Liabilities</b>		
<b>1 Non-current liabilities</b>		
(a) Financials Liabilities		
(i) Borrowings	51,691	37,243
(ii) Other financial liabilities	2,284	9,157
(b) Provisions	564	510
(c) Deferred tax liabilities (net)	397	377
(d) Other non-current liabilities	3,468	3,300
<b>Total non - current liabilities</b>	<b>58,404</b>	<b>50,587</b>
<b>2 Current liabilities</b>		
(a) Financials liabilities		
(i) Borrowings	4,999	174
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	14	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	18,152	14,249
(iii) Other financial liabilities	27,607	17,644
(b) Other current liabilities	3,228	2,853
(c) Provisions	728	560
(d) Income tax liabilities (net)	3	398
<b>Total current liabilities</b>	<b>54,731</b>	<b>35,878</b>
<b>Total equity and liabilities</b>	<b>165,355</b>	<b>144,367</b>
See accompanying notes to the Consolidated Financial Results		



## STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

## Notes:

1 The statement of audited consolidated financial results (the Statement) of HealthCare Global Enterprises Limited (the Company), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture, for the quarter and year ended 31 March 2019, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 23 May 2019. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The consolidated figures for the year ended 31 March 2019 have been audited by the Statutory Auditors of the Company. The reports of the Statutory Auditors are unqualified. The consolidated figures for the quarters ended 31 March 2019 and 31 March 2018 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review by the Statutory Auditors of the Company.

2 The statement of category wise utilisation of net proceeds from Initial Public Offer is:

Category wise utilisation of net proceeds from Initial Public Offer	Amount proposed to be utilised	Amount proposed to be utilised after reallocation	(Rs. in Lakhs)
			Actual utilisation upto 31 March 2019
Purchase of medical equipment	4,220	258	258
Investment in IT software, services and hardware	3,019	1,981	2,981 *
Pre-payment of debt	14,704	14,704	14,704
General corporate purposes	1,977	5,977	5,977
<b>Total</b>	<b>23,920</b>	<b>23,920</b>	<b>23,920</b>

(i) Rs. 3,962 lakhs from purchase of medical equipment and Rs. 38 lakhs from investment in IT software, services and hardware has been reallocated to General corporate purpose usage, as allowed by the 'Objects of the offer' section in the Prospectus of the Company for the Initial Public Offer.

\* Includes Rs. 1,000 lakhs ear-marked for meeting payment commitments with regard to a contract for supply of IT softwares.

- 3 During the year ended 31 March 2018, the Company has allotted 11,66,667 equity shares of Rs. 10 each at a premium of Rs. 290 per share on preferential basis, to Indgrowth Capital Fund I. There are no deviations in the proposed use of proceeds from the objects as stated in the explanatory statement to the notice for the general meeting.
- 4 Exceptional items:
- a During the year ended 31 March 2018, investment in HealthCare Global (Africa) Private Limited, is accounted under equity method as per Ind AS 28 'Investment in Associates and Joint Ventures' on account of change in control and the resultant gain of Rs. 640 lakhs is shown under exceptional items.
- b During the year ended 31 March 2018, the Company has entered into a business transfer agreement with Strand Life Sciences Private Limited (Strand) dated 2 January 2018 for sale of its Trieste unit on slump sale basis for a lumpsum consideration of Rs. 2,400 lakhs, for which the consideration is received in the form of 9,140,342 equity shares and 101,193 Series 1 Preference Shares of Strand resulting in gain on slump-sale (after eliminating inter-company gain) is Rs. 380 lakhs.
- c During the year ended 31 March 2018, the Delhi unit of the Company became non-operational. Net charge on account of write off of receivables is Rs. 218 lakhs and the charge due to write off of net fixed assets is Rs. 546 lakhs. The total charge due to this unit closure is Rs. 764 lakhs.
- d During the year ended 31 March 2018, in accordance with the terms of share purchase agreement entered into with Regency Hospital Limited dated 28 March 2018, the Company sold its long-term investments in equity shares held in its subsidiary, HCG Regency Oncology Healthcare Private Limited ('HCG Regency') for a total consideration of Rs. 2,123 lakhs resulting in a gain of Rs.821 lakhs. Pursuant to the above, HCG Regency has ceased to be subsidiary of the Company with effect from 29 March 2018.
- On account of a,b,c and d above, there is an exceptional gain of Rs. 437 Lakhs during the quarter ended and Rs. 1,077 lakhs for the year ended 31 March 2018.
- 5 During the year ended 31 March 2018, the Company had entered into a business transfer agreement with Dr. Gopichand (Seller) dated 28 February 2018 for purchase of business undertaking owned and operated by the Seller in the name of City Cancer Centre (CCC) located in Vijayawada. The Company has purchased the business on a slump sale basis for a sum consideration of Rs.5,200 lakhs payable partly by cash and partly by way of issuance of shares of the Company. Accordingly, Rs 1,500 lakhs was paid in cash during the year ended 31 March 2018, 934,500 equity shares of Rs. 10 at premium of Rs. 311 per share amounting to Rs 2,999 lakhs has been allotted to Dr. Gopichand during the year ended 31 March 2019 on preferential basis and the balance Rs 701 lakhs of contingent consideration will be paid as mutually agreed between the Company and the Seller.
- 6 During the year ended 31 March 2019, Apex Criticare LLP, holding 49.90% stake in one of the subsidiary of the Company, Apex HCG Oncology Hospitals LLP (Apex LLP) retired from Apex LLP and was paid an amount of Rs 2,525 lakhs as consideration. Pursuant to this, the Company along with its wholly owned subsidiary, Niruja Product Development and Healthcare Research Private Limited holds 100% interest in Apex LLP.
- 7 In accordance with the terms of the shareholders' agreement dated 22 March 2013 ('SHA') entered amongst the Company, BACC HealthCare Private Limited ('BACC') and the minority shareholder in BACC, the Company shall acquire the remaining 49.9% share capital of BACC from the minority shareholder as per the SHA. The consideration has been determined as per the terms of the SHA and will be settled within the period as mutually agreed between the Company and the minority shareholder.
- 8 The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.
- 9 Effective 1 April 2018 the Group has adopted Ind AS 115 - 'Revenue from Contracts with Customers' using the cumulative effect method. Accordingly, comparative periods were not restated. Based on the assessment, there is no material impact consequent to adoption of the standard.
- 10 At the Board meeting held on 23 May 2019, the Board of Directors of the Company has approved the proposal for issuance of 710,526 equity shares of Rs. 10 per share at a price of Rs. 285 per share (inclusive of face value of Rs. 10 per share), on Preferential Allotment basis, to Dr. Goc Varghese ('Investor'), subject to the approval of the shareholders of the Company in the proposed Extra Ordinary General Meeting.

For and on behalf of the Board of Directors

Dr. B. S. Ajalkumar  
Chairman and CEO

Bengaluru, 23 May 2019



Maruthi Info-Tech Centre  
11-12/1, B Block, 2nd Floor  
Inner Ring Road, Koramangala  
Bangalore 560 071 India

Telephone +91 80 7134 7000  
Fax +91 80 7134 7999

**Independent Auditors' Report on Annual standalone financial results of HealthCare Global Enterprises Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
Board of Directors of HealthCare Global Enterprises Limited

We have audited the annual standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the year ended 31 March 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that figures for the last quarter ended 31 March 2019 and the corresponding quarter ended in the previous year as reported in the Statement are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

The Statement has been prepared on the basis of the annual standalone financial statements and reviewed quarterly standalone financial results up to the end of the third quarter, which are the responsibility of the Company's Management. Our responsibility is to express an opinion on the Statement based on our audit of the annual standalone financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by Management. We believe that our audit provides a reasonable basis for our opinion.

1/23



**Independent Auditors' Report on Annual standalone financial results of HealthCare Global Enterprises Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)**

In our opinion and to the best of our information and according to the explanations given to us the Statement:

- (i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view of the net profit and other comprehensive income and other financial information for the year ended 31 March 2019.

For B S R & Co. LLP  
Chartered Accountants  
Firm's Registration No.101248W/  
W-100022

*Amit Somani*

Amit Somani  
Partner  
Membership No. 060154

Place: Bengaluru  
Date: 23 May 2019

## STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

(Rs. in Lakhs except share data)


Sl. No.	Particulars	3 months ended 31 March 2019	Preceding 3 months ended 31 December 2018	Corresponding 3 months ended in the previous year 31 March 2018	Year ended 31 March 2019	Previous year ended 31 March 2018
		(Refer note 1)	Unaudited	(Refer note 1)	Audited	Audited
1	<b>Income</b>					
	(a) Revenue from operations	16,561	15,936	15,195	64,050	58,027
	(b) Income from government grant	32	31	60	93	60
	(c) Other income	681	124	441	1,255	1,593
	<b>Total income</b>	<b>17,274</b>	<b>16,091</b>	<b>15,696</b>	<b>65,398</b>	<b>60,280</b>
2	<b>Expenses</b>					
	(a) Purchases of medical and non-medical items	3,674	3,682	3,532	15,254	15,782
	(b) Changes in inventories	133	196	302	7	(267)
	(c) Employee benefits expense	3,443	3,369	2,866	13,032	11,559
	(d) Finance costs	1,166	1,197	848	4,781	2,680
	(e) Depreciation and amortisation expense	1,264	1,217	1,164	4,717	4,392
	(f) Medical consultancy charges	3,042	3,190	2,033	11,965	10,340
	(g) Other expenses	3,942	3,374	4,043	14,315	12,400
	<b>Total expenses</b>	<b>16,664</b>	<b>16,126</b>	<b>14,788</b>	<b>64,141</b>	<b>56,886</b>
3	<b>Profit/(loss) before exceptional items and tax (1-2)</b>	<b>610</b>	<b>(35)</b>	<b>908</b>	<b>1,257</b>	<b>3,394</b>
4	Exceptional items [ refer note 4]	-	-	294	-	254
5	<b>Profit/(loss) before tax (3+4)</b>	<b>610</b>	<b>(35)</b>	<b>1,202</b>	<b>1,257</b>	<b>3,688</b>
6	<b>Tax expense</b>					
	- Current tax	(437)	-	312	(283)	863
	- Deferred tax	744	(17)	124	815	335
	<b>Total tax expense</b>	<b>307</b>	<b>(17)</b>	<b>436</b>	<b>532</b>	<b>1,198</b>
7	<b>Profit/ (loss) for the period / year (5-6)</b>	<b>303</b>	<b>(18)</b>	<b>766</b>	<b>725</b>	<b>2,490</b>
8	<b>Other comprehensive income / (expense)</b>					
	(i) Items that will not be reclassified subsequently to profit or loss					
	- Remeasurements of the defined benefit plans	12	-	(30)	12	(30)
	- Income tax effect on (i) above	(4)	-	10	(4)	10
	(ii) Items that will be reclassified to profit or loss					
	- Effective portion of loss on hedging instruments in a cash flow hedge	(24)	(219)	-	(643)	-
	- Income tax on (ii) above	8	75	-	223	-
	<b>Other comprehensive expense for the period / year, net of tax</b>	<b>(8)</b>	<b>(144)</b>	<b>(20)</b>	<b>(412)</b>	<b>(20)</b>
9	<b>Total comprehensive income/(loss) for the period / year (7+8)</b>	<b>295</b>	<b>(162)</b>	<b>746</b>	<b>313</b>	<b>2,470</b>
10	Paid-up equity share capital (Face value of Rs. 10 each)	8,792	8,789	8,690	8,792	8,690
11	Reserves, i.e., 'Other equity'				55,686	52,156
12	<b>Earnings/(loss) per equity share (face value of Rs. 10 each)</b>					
	(a) Basic	0.35	(0.02)	0.88	0.83	2.89
	(b) Diluted	0.35	(0.02)	0.88	0.82	2.89
	See accompanying notes to the Standalone Financial Results					



STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

STANDALONE BALANCE SHEET		(Rs in Lakhs)	
		As at 31 March 2019 Audited	As at 31 March 2018 Audited
<b>Particulars</b>			
<b>A</b>	<b>ASSETS</b>		
<b>I</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	49,164	43,907
	(b) Capital work in progress	10,411	7,911
	(c) Goodwill	4,845	4,845
	(d) Other intangible assets	670	447
	(e) Financial assets		
	(i) Investments	29,904	21,885
	(ii) Loans	4,523	3,383
	(iii) Other financial assets	7,932	2,935
	(f) Deferred tax assets (net)	314	910
	(g) Income tax assets (net)	4,642	1,747
	(h) Other non-current assets	4,892	3,493
	<b>Total non current assets</b>	<b>117,297</b>	<b>91,463</b>
<b>II</b>	<b>Current assets</b>		
	(a) Inventories	1,634	1,710
	(b) Financial assets		
	(i) Trade receivables	14,560	12,621
	(ii) Cash and cash equivalents	854	1,531
	(iii) Loans	1,284	292
	(iv) Other financial assets	2,414	1,814
	(c) Other current assets	2,315	1,795
	<b>Total current assets</b>	<b>23,061</b>	<b>19,763</b>
	<b>Total assets</b>	<b>140,358</b>	<b>111,226</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>I</b>	<b>Equity</b>		
	(a) Equity share capital	8,792	8,690
	(b) Shares pending issuance (refer note 5)	-	2,998
	(c) Other equity	55,680	52,156
	<b>Total equity</b>	<b>64,472</b>	<b>63,844</b>
<b>II</b>	<b>Liabilities</b>		
<b>I</b>	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	(i) Borrowings	34,615	21,724
	(ii) Other financial liabilities	2,975	2,211
	(b) Provisions	439	373
	(c) Other non-current liabilities	1,191	1,002
	<b>Total non-current liabilities</b>	<b>39,220</b>	<b>25,310</b>
<b>2</b>	<b>Current liabilities</b>		
	(a) Financial liabilities		
	(i) Borrowings	4,999	174
	(ii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	14	-
	Total outstanding dues of creditors other than micro enterprises and small enterprises	13,512	11,442
	(iii) Other financial liabilities	15,592	7,812
	(b) Other current liabilities	1,944	2,124
	(c) Provisions	605	520
	<b>Total current liabilities</b>	<b>36,666</b>	<b>22,072</b>
	<b>Total equity and liabilities</b>	<b>140,358</b>	<b>111,226</b>

See accompanying notes to the Standalone Financial Results



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd Office HCG Tower, No. 8, P Kaingra Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India  
Corp. Office Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

Notes:

1 The statement of audited standalone financial results (the Statement) of HealthCare Global Enterprises Limited (the Company) for the quarter and year ended 31 March 2019 has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meetings held on 23 May 2019. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 131 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 32 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The figures for the year ended 31 March 2019 have been audited by the statutory auditor of the Company. The report of the statutory auditor is unqualified. The figures for the quarters ended 31 March 2019 and 31 March 2018 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review by the statutory auditor of the Company.

2 The statement of category wise utilisation of net proceeds from Initial Public Offer is

Category wise utilisation of net proceeds from Initial Public Offer	Amount proposed to be utilised	Amount proposed to be utilised after reallocation	(Rs. in Lakhs)
			Actual utilisation upto 31 March 2019
Purchase of medical equipment	4,220	258	258
Investment in IT software, services and hardware	3,019	2,981	2,981*
Pre-payment of debt	14,704	14,704	14,704
General corporate purposes	1,977	5,977	5,977
<b>Total</b>	<b>23,920</b>	<b>23,920</b>	<b>23,920</b>

(i) Rs. 3,962 lakhs from purchase of medical equipment and Rs. 38 lakhs from investment in IT software, services and hardware has been reallocated to General corporate purpose usage, as allowed by the 'Objects of the offer' section in the Prospectus of the Company for the Initial Public Offer.

\* Includes Rs. 1,000 lakhs set-aside for meeting payment commitments with regard to a contract for supply of IT softwares.

3 During the year ended 31 March 2018, the Company has allotted 11,66,667 equity shares of Rs. 10 each at a premium of Rs. 290 per share on preferential basis, to Indragrath Capital Fund I. There are no deviations in the proposed use of proceeds from the objects has stated in the explanatory statement to the notice for the general meeting.

4 Exceptional items:

a During the year ended 31 March 2018, the Company has entered into a business transfer agreement with Strand Life Sciences Private Limited ('Strand') dated 2 January 2018 for sale of its Trieste unit on slump sale basis for a lumpsum consideration of Rs. 2,400 lakhs for which the consideration is received in the form of 9,140,342 equity shares and 101,193 Series 1 Preference Shares of Strand resulting in a gain of Rs. 614 lakhs.

b During the year ended 31 March 2018, the Delhi unit of the Company became non-operational. Net charge on account of write off of receivables is Rs. 218 lakhs and the charge due to write off of net fixed assets is Rs. 546 lakhs. The total charge due to this unit closure is Rs. 764 lakhs.

c During the year ended 31 March 2018, in accordance with the terms of share purchase agreement entered into with Regency Hospital Limited dated 28 March 2018, the Company sold its long-term investments in equity shares held in HCG Regency Oncology HealthCare Private Limited (HCG Regency) for a total consideration of Rs. 2,123 lakhs resulting in a gain of Rs. 444 lakhs. Pursuant to the above, HCG Regency has ceased to be subsidiary of the Company with effect from 29 March 2018.

On account of a, b and c above, there is an exceptional gain of Rs. 294 lakhs during the quarter and year ended 31 March 2018.

5 During the year ended 31 March 2018, the Company had entered into a business transfer agreement with Dr. Gopichand (Seller) dated 28 February 2018 for purchase of business undertaking owned and operated by the Seller in the name of City Cancer Centre (CCC) located in Vijayawada. The Company has purchased the business on a slump sale basis for a sum consideration of Rs. 5,200 lakhs payable partly by cash and partly by way of issuance of shares of the Company. Accordingly, Rs. 1,500 lakhs was paid in cash during the year ended 31 March 2018, 934,500 equity shares of Rs. 10 at premium of Rs. 311 per share amounting to Rs. 2,999 lakhs has been allotted to Dr. Gopichand during the year ended 31 March 2019 on preferential basis and the balance Rs. 701 lakhs of contingent consideration will be paid as mutually agreed between the Company and the Seller.

6 During the year ended 31 March 2019, Apex Criticare LLP, holding 49.90% stake in one of the subsidiary of the Company, Apex HCG Oncology Hospitals LLP (Apex LLP) retired from Apex LLP and was paid an amount of Rs. 2,525 lakhs as consideration. Pursuant to this, the Company along with its wholly owned subsidiary, Niruja Product Development and Healthcare Research Private Limited holds 100% interest in Apex LLP.

7 In accordance with the terms of the shareholders' agreement dated 22 March 2013 ('SHA') entered amongst the Company, BACC HealthCare Private Limited ('BACC') and the minority shareholder in BACC, the Company shall acquire the remaining 49.9% share capital of BACC from the minority shareholder as per the SHA. The consideration has been determined as per the terms of the SHA and will be settled within the period as mutually agreed between the Company and the minority shareholder.

8 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

9 Effective 1 April 2018 the Company has adopted Ind AS 115 - 'Revenue from Contracts with Customers' using the cumulative effect method. Accordingly, comparative periods were not restated. Based on the assessment, there is no material impact consequent to adoption of the standard.

10 At the Board meeting held on 23 May 2019, the Board of Directors of the Company has approved the proposal for issuance of 710,526 equity shares of Rs. 10 per share at a price of Rs. 285 per share (inclusive of face value of Rs. 10 per share), on Preferential Allotment basis, to Dr. Gea Varghese ('Investor'), subject to the approval of the shareholders of the Company in the proposed Extra Ordinary General Meeting.

For and on behalf of the Board of Directors

Dr. R. S. Ajith Kumar  
Chairman and CEO

Bengaluru, 23 May 2019

